Stay updated with breaking news from Cell Specific. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Eureka Therapeutics Announces Publication of Study Demonstrating Broad Anti-Tumor Activity of TCR Mimic-Redirected T Cells Targeting NDC80 - read this article along with other careers information, tips and advice on BioSpace
EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the publication of a preclinical study in blood entitled “A TCR Mimic CAR T Cell Specific for NDC80 Is Broadly Reactive With Solid Tumors and...
Chronic lymphocytic leukemia (CLL) has experienced a clinical revolution thanks to the discovery of crucial pathogenetic mechanisms. CLL is still an incurable disease due to intrinsic or acquired resistance of the leukemic clone. Venetoclax is a Bcl-2 inhibitor with a marked activity in CLL, but emerging patterns of resistance are being described. We hypothesize that intrinsic features of CLL cells may contribute to drive mechanisms of resistance to venetoclax. We analyzed the expression of IRF4, Notch2 and Mcl-1 in a cohort of CLL patients. We evaluated CLL cells viability after genetic and p...